Lower airway colonization and inflammatory response in COPD: A focus on Haemophilus influenza

International Journal of COPD

Volumn 9, Issue , 2014, Pages 1119-1132

  Finney, Lydia J ^a   Ritchie, Andrew ^a   Pollard, Elizabeth ^b   Johnston, Sebastian L ^a   Mallia, Patrick ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Haemophilus influenzae; Nontypeable Haemophilus influenzae; Respiratory viruses; Vaccination

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE VACCINE; IMMUNOGLOBULIN A; MACROLIDE; HAEMOPHILUS VACCINE;

ADAPTIVE IMMUNITY; ANTIGENICITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL METABOLISM; BACTERIAL STRAIN; BACTERIOLOGY; BACTERIUM ADHERENCE; BACTERIUM CULTURE; BACTERIUM DETECTION; BIOFILM; CELLULAR IMMUNITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPLEMENT ACTIVATION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SURVEILLANCE; DRUG EFFECT; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; IMMUNE EVASION; INFECTION PREVENTION; LOWER RESPIRATORY TRACT; LUNG STRUCTURE; NONHUMAN; OUTCOME ASSESSMENT; QUALITY OF LIFE; RESPIRATORY TRACT INFLAMMATION; RESPIRATORY VIRUS; TREATMENT PLANNING; VACCINATION; VIRAL RESPIRATORY TRACT INFECTION; ANIMAL; HAEMOPHILUS INFECTIONS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INNATE IMMUNITY; LUNG; MICROBIOLOGY; PATHOGENICITY; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS;

ADAPTIVE IMMUNITY; ANIMALS; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; LUNG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS;

EID: 84907813962     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S54477     Document Type: Article

References (146)

1. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28(3):523-532.
2. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med. 2009;360(23):2445-2454.
3. Lapperre TS, Postma DS, Gosman MM, et al. Relation between duration of smoking cessation and bronchial inflammation in COPD. Thorax. 2006;61(2):115-121.
4. Alikhan MM, Lee FE. Understanding nontypeable Haemophilus influenzae and chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2014;20(2):159-164.
5. Singanayagam A, Joshi PV, Mallia P, Johnston SL. Viruses exacerbating chronic pulmonary disease: the role of immune modulation. BMC Med. 2012;10(1):27.
6. Beasley V, Joshi PV, Singanayagam A, Molyneaux PL, Johnston SL, Mallia P. Lung microbiology and exacerbations in COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:555-569.
7. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005;128(4):1995-2004.
8. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847-852.
9. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418-1422.
10. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173(10):1114-1121.
11. King P. Haemophilus influenzae and the lung (Haemophilus and the lung). Clin Transl Med. 2012;1(1):10.
12. Fontanals D, Bou R, Pons I, et al. Prevalence of Haemophilus influenzae carriers in the Catalan preschool population. Working Group on Invasive Disease Caused by Haemophilus influenzae. Eur J Clin Microbiol Infect Dis. 2000;19(4):301-304.
13. Rosell A, Monsó E, Soler N, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med. 2005;165(8):891-897.
14. Bandi V, Apicella MA, Mason E, et al. Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am J Respir Crit Care Med. 2001;164(11):2114-2119.
15. Sethi S, Maloney J, Grove L, Wrona C, Berenson CS. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173(9):991-998.
16. Clementi CF, Murphy TF. Non-typeable Haemophilus influenzae invasion and persistence in the human respiratory tract. Front Cell Infect Microbiol. 2011;1:1.
17. Janson H, Ruan M, Forsgren A. Limited diversity of the protein D gene (hpd) among encapsulated and nonencapsulated Haemophilus influenzae strains. Infect Immun. 1993;61(11):4546-4552.
18. Wang X, Mair R, Hatcher C, et al. Detection of bacterial pathogens in Mongolia meningitis surveillance with a new real-time PCR assay to detect Haemophilus influenzae. Int J Med Microbiol. 2011;301(4):303-309.
19. Ueyama T, Kurono Y, Shirabe K, Takeshita M, Mogi G. High incidence of Haemophilus influenzae in nasopharyngeal secretions and middle ear effusions as detected by PCR. J Clin Microbiol. 1995;33(7):1835-1838.
20. Tian GZ, Zhang LJ, Wang XL, et al. Rapid detection of Haemophilus influenzae and Haemophilus parainfluenzae in nasopharyngeal swabs by multiplex PCR. Biomed Environ Sci. 2012;25(3):367-371.
21. Binks MJ, Temple B, Kirkham LA, et al. Molecular surveillance of true nontypeable Haemophilus influenzae: an evaluation of PCR screening assays. PLoS ONE. 2012;7(3):e34083.
22. Zhu B, Xiao D, Zhang H, et al. MALDI-TOF MS distinctly differentiates nontypable Haemophilus influenzae from Haemophilus haemolyticus. PLoS ONE. 2013;8(2):e56139.
23. Dickson RP, Erb-Downward JR, Huffnagle GB. The role of the bacterial microbiome in lung disease. Expert Rev Respir Med. 2013;7(3):245-257.
24. Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PLoS ONE. 2010;5(1):e8578.
25. Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax. 2002;57(9):759-764.
26. Wilkinson TM, Patel IS, Wilks M, Donaldson GC, Wedzicha JA. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167(8):1090-1095.
27. Hurst JR, Wilkinson TM, Perera WR, Donaldson GC, Wedzicha JA. Relationships among bacteria, upper airway, lower airway, and systemic inflammation in COPD. Chest. 2005;127(4):1219-1226.
28. Murphy TF, Brauer AL, Schiffmacher AT, Sethi S. Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170(3):266-272.
29. Garcha DS, Thurston SJ, Patel AR, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax. 2012;67(12):1075-1080.
30. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662-671.
31. Curran T, Coyle PV, McManus TE, Kidney J, Coulter WA. Evaluation of real-time PCR for the detection and quantification of bacteria in chronic obstructive pulmonary disease. FEMS Immunol Med Microbiol. 2007;50(1):112-118.
32. Groenewegen KH, Wouters EF. Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1-year prospective study. Respir Med. 2003;97(7):770-777.
33. Molyneaux PL, Mallia P, Cox MJ, et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188(10):1224-1231.
34. Huang YJ, Sethi S, Murphy T, Nariya S, Boushey HA, Lynch SV. Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease. J Clin Microbiol. 2014;52(8):2813-2823.
35. Rogers GB, van der Gast CJ, Serisier DJ. Predominant pathogen competition and core microbiota divergence in chronic airway infection. ISME J. 2014. Epub ahead of print http://dx.doi.org/10.1038/ismej.2014.124.
36. Knowles MR, Daniels LA, Davis SD, Zariwala MA, Leigh MW. Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease. Am J Respir Crit Care Med. 2013;188(8):913-922.
37. Wieland CW, Florquin S, Maris NA, et al. The MyD88-dependent, but not the MyD88-independent, pathway of TLR4 signaling is important in clearing nontypeable haemophilus influenzae from the mouse lung. J Immunol. 2005;175(9):6042-6049.
38. Reddy MS, Murphy TF, Faden HS, Bernstein JM. Middle ear mucin glycoprotein: purification and interaction with nontypable Haemophilus influenzae and Moraxella catarrhalis. Otolaryngol Head Neck Surg. 1997;116(2):175-180.
39. Miyamoto N, Bakaletz LO. Selective adherence of non-typeable Haemophilus influenzae (NTHi) to mucus or epithelial cells in the chinchilla eustachian tube and middle ear. Microb Pathog. 1996;21(5):343-356.
40. Berenson CS, Garlipp MA, Grove LJ, Maloney J, Sethi S. Impaired phagocytosis of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic obstructive pulmonary disease. J Infect Dis. 2006;194(10):1375-1384.
41. Hallström T, Riesbeck K. Haemophilus influenzae and the complement system. Trends Microbiol. 2010;18(6):258-265.
42. Marc MM, Korosec P, Kosnik M, et al. Complement factors c3a, c4a, and c5a in chronic obstructive pulmonary disease and asthma. Am J Respir Cell Mol Biol. 2004;31(2):216-219.
43. Marc MM, Kristan SS, Rozman A, et al. Complement factor C5a in acute exacerbation of Chronic Obstructive Pulmonary Disease. Scand J Immunol. 2010;71(5):386-391.
44. Woof JM, Kerr MA. The function of immunoglobulin A in immunity. J Pathol. 2006;208(2):270-282.
45. Ram S, Lewis LA, Rice PA. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev. 2010;23(4):740-780.
46. Kainulainen L, Nikoskelainen J, Vuorinen T, Tevola K, Liippo K, Ruuskanen O. Viruses and bacteria in bronchial samples from patients with primary hypogammaglobulinemia. Am J Respir Crit Care Med. 1999;159(4 Pt 1):1199-1204.
47. King P., Hutchinson PE, Johnson PD, Holmes PW, Freezer NJ, Holdsworth SR. Adaptive immunity to nontypeable Haemophilus influenzae. Am J Respir Crit Care Med. 2003;167(4):587-592.
48. King P., Ngui J, Gunawardena D, Holmes PW, Farmer MW, Holdsworth SR. Systemic humoral immunity to non-typeable Haemophilus influenzae. Clin Exp Immunol. 2008;153(3):376-384.
49. King P, Ngui J, Oppedisano F, Robins-Browne R, Holmes P, Holdsworth S. Effect of interferon gamma and CD40 ligation on intracellular monocyte survival of nontypeable Haemophilus influenzae. APMIS. 2008;116(12):1043-1049.
50. King P., Ngui J, Farmer MW, Hutchinson P, Holmes PW, Holdsworth SR. Cytotoxic T lymphocyte and natural killer cell responses to non-typeable Haemophilus influenzae. Clin Exp Immunol. 2008;152(3):542-551.
51. van Ham SM, van Alphen L, Mooi FR, van Putten JP. Phase variation of H. influenzae fimbriae: transcriptional control of two divergent genes through a variable combined promoter region. Cell. 1993;73(6):1187-1196.
52. Erwin AL, Smith AL. Nontypeable Haemophilus influenzae: understanding virulence and commensal behavior. Trends Microbiol. 2007;15(8):355-362.
53. Duim B, Vogel L, Puijk W, et al. Fine mapping of outer membrane protein P2 antigenic sites which vary during persistent infection by Haemophilus influenzae. Infect Immun. 1996;64(11):4673-4679.
54. Cholon DM, Cutter D, Richardson SK, et al. Serial isolates of persistent Haemophilus influenzae in patients with chronic obstructive pulmonary disease express diminishing quantities of the HMW1 and HMW2 adhesins. Infect Immun. 2008;76(10):4463-4468.
55. Swords WE. Nontypeable Haemophilus influenzae biofilms: role in chronic airway infections. Front Cell Infect Microbiol. 2012;2:97.
56. Murphy TF, Kirkham C. Biofilm formation by nontypeable Haemophilus influenzae: strain variability, outer membrane antigen expression and role of pili. BMC Microbiol. 2002;2(1):7.
57. Murphy TF, Kirkham C, Sethi S, Lesse AJ. Expression of a peroxiredoxin-glutaredoxin by Haemophilus influenzae in biofilms and during human respiratory tract infection. FEMS Immunol Med Microbiol. 2005;44(1):81-89.
58. Langereis JD, Hermans PW. Novel concepts in nontypeable Haemophilus influenzae biofilm formation. FEMS Microbiol Lett. 2013;346(2):81-89.
59. St Geme JW III, Falkow S. Loss of capsule expression by Haemophilus influenzae type b results in enhanced adherence to and invasion of human cells. Infect Immun. 1991;59(4):1325-1333.
60. St Geme JW III, Falkow S. Haemophilus influenzae adheres to and enters cultured human epithelial cells. Infect Immun. 1990;58(12):4036-4044.
61. Forsgren J, Samuelson A, Ahlin A, Jonasson J, Rynnel-Dagöö B, Lindberg A. Haemophilus influenzae resides and multiplies intracellularly in human adenoid tissue as demonstrated by in situ hybridization and bacterial viability assay. Infect Immun. 1994;62(2):673-679.
62. Forsgren J, Samuelson A, Lindberg A, Rynnel-Dagöö B. Quantitative bacterial culture from adenoid lymphatic tissue with special reference to Haemophilus [corrected]. [corrected]. Acta Otolaryngol. 1993;113(5): 668-672.
63. Ahrén IL, Janson H, Forsgren A, Riesbeck K. Protein D expression promotes the adherence and internalization of non-typeable Haemophilus influenzae into human monocytic cells. Microb Pathog. 2001;31(3):151-158.
64. van Schilfgaarde M, Eijk P, Regelink A, et al. Haemophilus influenzae localized in epithelial cell layers is shielded from antibiotics and antibody-mediated bactericidal activity. Microb Pathog. 1999;26(5):249-262.
65. Su YC, Jalalvand F, Mörgelin M, Blom AM, Singh B, Riesbeck K. Haemophilus influenzae acquires vitronectin via the ubiquitous Protein F to subvert host innate immunity. Mol Microbiol. 2013;87(6):1245-1266.
66. Hallström T, Trajkovska E, Forsgren A, Riesbeck K. Haemophilus influenzae surface fibrils contribute to serum resistance by interacting with vitronectin. J Immunol. 2006;177(1):430-436.
67. Hallström T, Zipfel PF, Blom AM, Lauer N, Forsgren A, Riesbeck K. Haemophilus influenzae interacts with the human complement inhibitor factor H. J Immunol. 2008;181(1):537-545.
68. Kilian M, Mestecky J, Russell MW. Defense mechanisms involving Fc-dependent functions of immunoglobulin A and their subversion by bacterial immunoglobulin A proteases. Microbiol Rev. 1988;52(2):296-303.
69. Murphy TF, Brauer AL. Expression of urease by Haemophilus influenzae during human respiratory tract infection and role in survival in an acid environment. BMC Microbiol. 2011;11(1):183.
70. Whitby PW, Morton DJ, Vanwagoner TM, et al. Haemophilus influenzae OxyR: characterization of its regulation, regulon and role in fitness. PLoS ONE. 2012;7(11):e50588.
71. Whitby PW, VanWagoner TM, Seale TW, Morton DJ, Stull TL. Comparison of transcription of the Haemophilus influenzae iron/heme modulon genes in vitro and in vivo in the chinchilla middle ear. BMC Genomics. 2013;14(1):925.
72. Qu J, Lesse AJ, Brauer AL, Cao J, Gill SR, Murphy TF. Proteomic expression profiling of Haemophilus influenzae grown in pooled human sputum from adults with chronic obstructive pulmonary disease reveal antioxidant and stress responses. BMC Microbiol. 2010;10(1):162.
73. Zhang L, Patel M, Xie J, Davis GS, Marrs CF, Gilsdorf JR. Urease operon and urease activity in commensal and disease-causing nontypeable Haemophilus influenzae. J Clin Microbiol. 2013;51(2): 653-655.
74. Zhang L, Xie J, Patel M, et al. Nontypeable Haemophilus influenzae genetic islands associated with chronic pulmonary infection. PLoS ONE. 2012;7(9):e44730.
75. St Geme JW, Pinkner JS III, Krasan GP, et al. Haemophilus influenzae pili are composite structures assembled via the HifB chaperone. Proc Natl Acad Sci USA. 1996;93(21):11913-11918.
76. Hallström T, Singh B, Resman F, Blom AM, Mörgelin M, Riesbeck K. Haemophilus influenzae protein E binds to the extracellular matrix by concurrently interacting with laminin and vitronectin. J Infect Dis. 2011;204(7):1065-1074.
77. Jalalvand F, Su YC, Mörgelin M, et al. Haemophilus influenzae protein F mediates binding to laminin and human pulmonary epithelial cells. J Infect Dis. 2013;207(5):803-813.
78. St Geme JW III, Falkow S, Barenkamp SJ. High-molecular-weight proteins of nontypable Haemophilus influenzae mediate attachment to human epithelial cells. Proc Natl Acad Sci U S A. 1993;90(7): 2875-2879.
79. Johnson RW, McGillivary G, Denoël P, Poolman J, Bakaletz LO. Abrogation of nontypeable Haemophilus influenzae protein D function reduces phosphorylcholine decoration, adherence to airway epithelial cells, and fitness in a chinchilla model of otitis media. Vaccine. 2011;29(6):1211-1221.
80. Denny FW. Effect of a toxin produced by Haemophilus influenzae on ciliated respiratory epithelium. J Infect Dis. 1974;129(2):93-100.
81. Janson H, Carln B, Cervin A, et al. Effects on the ciliated epithelium of protein D-producing and-nonproducing nontypeable Haemophilus influenzae in nasopharyngeal tissue cultures. J Infect Dis. 1999;180(3): 737-746.
82. van Schilfgaarde M, van Ulsen P, Eijk P, et al. Characterization of adherence of nontypeable Haemophilus influenzae to human epithelial cells. Infect Immun. 2000;68(8):4658-4665.
83. Berenson CS, Kruzel RL, Eberhardt E, et al. Impaired innate immune alveolar macrophage response and the predilection for COPD exacerbations. Thorax. 2014;69(9):811-818.
84. Berenson CS, Kruzel RL, Eberhardt E, Sethi S. Phagocytic dysfunction of human alveolar macrophages and severity of chronic obstructive pulmonary disease. J Infect Dis. 2013;208(12):2036-2045.
85. Taylor AE, Finney-Hayward TK, Quint JK, et al. Defective macrophage phagocytosis of bacteria in COPD. Eur Respir J. 2010;35(5):1039-1047.
86. Berenson CS, Wrona CT, Grove LJ, et al. Impaired alveolar macrophage response to Haemophilus antigens in chronic obstructive lung disease. Am J Respir Crit Care Med. 2006;174(1):31-40.
87. Craig JE, Cliffe A, Garnett K, High NJ. Survival of nontypeable Haemophilus influenzae in macrophages. FEMS Microbiol Lett. 2001;203(1):55-61.
88. Clementi CF, Håkansson AP, Murphy TF. Internalization and trafficking of nontypeable Haemophilus influenzae in human respiratory epithelial cells and roles of IgA1 proteases for optimal invasion and persistence. Infect Immun. 2014;82(1):433-444.
89. Knobloch J, Schild K, Jungck D, et al. The T-helper cell type 1 immune response to gram-negative bacterial infections is impaired in COPD. Am J Respir Crit Care Med. 2011;183(2):204-214.
90. Abe Y, Murphy TF, Sethi S, et al. Lymphocyte proliferative response to P6 of Haemophilus influenzae is associated with relative protection from exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;165(7):967-971.
91. Kalathil SG, Lugade AA, Pradhan V, et al. T-regulatory cells and programmed death 1+ T cells contribute to effector T-cell dysfunction in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;190(1):40-50.
92. Duim B, Bowler LD, Eijk PP, Jansen HM, Dankert J, van Alphen L. Molecular variation in the major outer membrane protein P5 gene of nonencapsulated Haemophilus influenzae during chronic infections. Infect Immun. 1997;65(4):1351-1356.
93. Duim B, van Alphen L, Eijk P, Jansen HM, Dankert J. Antigenic drift of non-encapsulated Haemophilus influenzae major outer membrane protein P2 in patients with chronic bronchitis is caused by point mutations. Mol Microbiol. 1994;11(6):1181-1189.
94. Lomholt H, van Alphen L, Kilian M. Antigenic variation of immunoglobulin A1 proteases among sequential isolates of Haemophilus influenzae from healthy children and patients with chronic obstructive pulmonary disease. Infect Immun. 1993;61(11):4575-4581.
95. Polosukhin VV, Cates JM, Lawson WE, et al. Bronchial secretory immunoglobulin a deficiency correlates with airway inflammation and progression of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;184(3):317-327.
96. Murphy TF, Lesse AJ, Kirkham C, Zhong H, Sethi S, Munson RS Jr. A clonal group of nontypeable Haemophilus influenzae with two IgA proteases is adapted to infection in chronic obstructive pulmonary disease. PLoS ONE. 2011;6(10):e25923.
97. Millares L, Marin A, Garcia-Aymerich J, Sauleda J, Belda J, Monsó E; PAC-COPD Study Group. Specific IgA and metalloproteinase activity in bronchial secretions from stable chronic obstructive pulmonary disease patients colonized by Haemophilus influenzae. Respir Res. 2012;13(1):113.
98. Marin A, Garcia-Aymerich J, Sauleda J, et al; PAC-COPD Study Group. Effect of bronchial colonisation on airway and systemic inflammation in stable COPD. COPD. 2012;9(2):121-130.
99. Desai H, Eschberger K, Wrona C, et al. Bacterial colonization increases daily symptoms in patients with chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11(3):303-309.
100. Beasley V, Joshi PV, Singanayagam A, Molyneaux PL, Johnston SL, Mallia P. Lung microbiology and exacerbations in COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:555-569.
101. Moghaddam SJ, Clement CG, De la Garza MM, et al. Haemophilus influenzae lysate induces aspects of the chronic obstructive pulmonary disease phenotype. Am J Respir Cell Mol Biol. 2008;38(6):629-638.
102. Ganesan S, Comstock AT, Kinker B, Mancuso P, Beck JM, Sajjan US. Combined exposure to cigarette smoke and nontypeable Haemophilus influenzae drives development of a COPD phenotype in mice. Respir Res. 2014;15(1):11.
103. Bresser P, Out TA, van Alphen L, Jansen HM, Lutter R. Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic haemophilus influenzae airway infection. Comparison with noninfected patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162(3 Pt 1):947-952.
104. Marin A, Monsó E, Garcia-Nuñez M, et al. Variability and effects of bronchial colonisation in patients with moderate COPD. Eur Respir J. 2010;35(2):295-302.
105. Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173(1):71-78.
106. Wilkinson TM, Hurst JR, Perera WR, Wilks M, Donaldson GC, Wedzicha JA. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest. 2006; 129(2):317-324.
107. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;347(7):465-471.
108. Murphy TF, Brauer AL, Sethi S, Kilian M, Cai X, Lesse AJ. Haemophilus haemolyticus: a human respiratory tract commensal to be distinguished from Haemophilus influenzae. J Infect Dis. 2007;195(1):81-89.
109. Sethi S, Wrona C, Grant BJ, Murphy TF. Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;169(4):448-453.
110. Fernaays MM, Lesse AJ, Sethi S, Cai X, Murphy TF. Differential genome contents of nontypeable Haemophilus influenzae strains from adults with chronic obstructive pulmonary disease. Infect Immun. 2006;74(6):3366-3374.
111. Chin CL, Manzel LJ, Lehman EE, et al. Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers. Am J Respir Crit Care Med. 2005;172(1):85-91.
112. Geelen TH, Gaajetaan GR, Wouters EF, et al. The host immune response contributes to Haemophilus influenzae virulence. Respir Med. 2014;108(1):144-152.
113. Wang XY, Kilgore PE, Lim KA, et al. Influenza and bacterial pathogen coinfections in the 20th century. Interdiscip Perspect Infect Dis. 2011;2011:146376.
114. Lee LN, Dias P, Han D, et al. A mouse model of lethal synergism between influenza virus and Haemophilus influenzae. Am J Pathol. 2010;176(2):800-811.
115. Zwaans WA, Mallia P, van Winden ME, Rohde GG. The relevance of respiratory viral infections in the exacerbations of chronic obstructive pulmonary disease-A systematic review. J Clin Virol. 2014. Epub ahead of print http://dx.doi.org/10.1016/j.jcv.2014.06.025.
116. Unger BL, Faris AN, Ganesan S, Comstock AT, Hershenson MB, Sajjan US. Rhinovirus attenuates non-typeable Hemophilus influenzae-stimulated IL-8 responses via TLR2-dependent degradation of IRAK-1. PLoS Pathog. 2012;8(10):e1002969.
117. Oliver BG, Lim S, Wark P, et al. Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages. Thorax. 2008;63(6):519-525.
118. Comstock AT, Ganesan S, Chattoraj A, et al. Rhinovirus-induced barrier dysfunction in polarized airway epithelial cells is mediated by NADPH oxidase 1. J Virol. 2011;85(13):6795-6808.
119. Wang JH, Kwon HJ, Jang YJ. Rhinovirus enhances various bacterial adhesions to nasal epithelial cells simultaneously. Laryngoscope. 2009;119(7):1406-1411.
120. Wang JH, Lee SH, Kwon HJ, Jang YJ. Clarithromycin inhibits rhinovirus-induced bacterial adhesions to nasal epithelial cells. Laryngoscope. 2010;120(1):193-199.
121. Avadhanula V, Rodriguez CA, Devincenzo JP, et al. Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species-and cell type-dependent manner. J Virol. 2006;80(4):1629-1636.
122. Suri R, Mallia P, Martin JE, et al. Bronchial platelet-activating factor receptor in chronic obstructive pulmonary disease. Respir Med. 2014;108(6):898-904.
123. Bandi V, Jakubowycz M, Kinyon C, et al. Infectious exacerbations of chronic obstructive pulmonary disease associated with respiratory viruses and non-typeable Haemophilus influenzae. FEMS Immunol Med Microbiol. 2003;37(1):69-75.
124. Mallia P, Footitt J, Sotero R, et al. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(11):1117-1124.
125. Hutchinson AF, Ghimire AK, Thompson MA, et al. A community-based, time-matched, case-control study of respiratory viruses and exacerbations of COPD. Respir Med. 2007;101(12):2472-2481.
126. George SN, Garcha DS, Mackay AJ, et al. Human rhinovirus infection during naturally occurring COPD exacerbations. Eur Respir J. 2014;44(1):87-96.
127. Sajjan US, Jia Y, Newcomb DC, et al. H. influenzae potentiates airway epithelial cell responses to rhinovirus by increasing ICAM-1 and TLR3 expression. FASEB J. 2006;20(12):2121-2123.
128. Agrawal A, Murphy TF. Haemophilus influenzae infections in the H. influenzae type b conjugate vaccine era. J Clin Microbiol. 2011;49(11):3728-3732.
129. Hiltke TJ, Schiffmacher AT, Dagonese AJ, Sethi S, Murphy TF. Horizontal transfer of the gene encoding outer membrane protein P2 of nontypeable Haemophilus influenzae, in a patient with chronic obstructive pulmonary disease. J Infect Dis. 2003;188(1):114-117.
130. Ostberg KL, Russell MW, Murphy TF. Mucosal immunization of mice with recombinant OMP P2 induces antibodies that bind to surface epitopes of multiple strains of nontypeable Haemophilus influenzae. Mucosal Immunol. 2009;2(1):63-73.
131. Poolman JT, Bakaletz L, Cripps A, et al. Developing a nontypeable Haemophilus influenzae (NTHi) vaccine. Vaccine. 2000; 19(Suppl 1):S108-S115.
132. Novotny LA, Jurcisek JA, Godfroid F, Poolman JT, Denoël PA, Bakaletz LO. Passive immunization with human anti-protein D antibodies induced by polysaccharide protein D conjugates protects chinchillas against otitis media after intranasal challenge with Haemophilus influenzae. Vaccine. 2006;24(22):4804-4811.
133. Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet. 2006;367(9512):740-748.
134. Hawdon N, Biman B, McCready W, et al. Antibody against Haemophilus influenzae protein D in patients with chronic conditions causing secondary immunodeficiency. Vaccine. 2012;30(7):1235-1238.
135. Clancy R., Dunkley M. A vaccine to prevent exacerbations in COPD. Med J Aust. 2011;195(2):99-100.
136. Teo E, House H, Lockhart K, Purchuri SN, Pushparajah J, Cripps AW, van Driel ML. Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;9: CD010010.
137. Tandon MK, Phillips M, Waterer G, Dunkley M, Comans P, Clancy R. Oral immunotherapy with inactivated nontypeable Haemophilus influenzae reduces severity of acute exacerbations in severe COPD. Chest. 2010;137(4):805-811.
138. Collet JP, Shapiro P, Ernst P, Renzi T, Ducruet T, Robinson A. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant. Am J Respir Crit Care Med. 1997;156(6):1719-1724.
139. Cvoriscec B, Ustar M, Pardon R, Palecek I, Stipic-Markovic A, Zimic B. Oral immunotherapy of chronic bronchitis: a double-blind placebo-controlled multicentre study. Respiration. 1989;55(3):129-135.
140. Arandjus C, Black PN, Poole PJ, Wood Baker R, Steurer-Stey C. Oral bacterial vaccines for the prevention of acute exacerbations in chronic obstructive pulmonary disease and chronic bronchitis. Respir Med. 2006;100(10):1671-1681.
141. He ZY, Ou LM, Zhang JQ, et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration. 2010;80(6):445-452.
142. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178(11):1139-1147.
143. Albert RK, Connett J, Bailey WC, et al; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689-698.
144. Sethi S, Jones PW, Theron MS, et al; PULSE Study group. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res. 2010;11(1):10.
145. Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J. 2010;36(3):646-654.
146. Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med. 2013;1(3):262-274.